|Peer review refers to the work done during the screening of submitted manuscripts and funding applications. This process encourages authors to meet the accepted standards of their discipline and reduces the dissemination of irrelevant findings, unwarranted claims, unacceptable interpretations, and personal views. Publications that have not undergone peer review are likely to be regarded with suspicion by academic scholars and professionals.
Circulating Tumor Cells (CTCs), shed into the bloodstream from primary and metastatic tumors are regarded as the liquid biopsy of cancer is an enthusiastic field of research which attracted half-a thousand publications in the recent two decades. The Circulating Tumor Cells research can be categorized into three major aspects: 1) Clinically focused on the applications of Circulating Tumor Cells as biomarkers for cancer diagnosis, progression, prognosis and therapeutics; 2) Molecular characterization of Circulating Tumor Cells to determine their clinical relevance and functional activities in tumor microenvironments; and 3) Technological investment in detection and isolation of rare Circulating Tumor Cells from peripheral blood specimens and even in vivo tracking of Circulating Tumor Cells. High Circulating Tumor Cells numbers have been correlated with increased metastasis and decreased time to relapse, which supporting the predictive values on cancer progression, prognosis and survival in several cancers. A meta-analysis of 49 eligible studies enrolling 6,825 breast cancer patients indicated Circulating Tumor Cells a stable prognostic biomarker at both earlyand metastatic stages. Such encouraging reports have directed many investigators into the search of various strategies in Circulating Tumor Cells enrichment to achieve the limit of detection at one Circulating Tumor Cells per million cells level.(John YWM, Mayur-Danny GI, Circulating Tumor Cells â Cutting Edge Research?)